trial · primary record
Brigatinib
Neurofibromatosis Type 2
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 109 |
| Primary completion | 2030-12-01 |
| Primary endpoint | Radiographic response rate (for each drug substudy) |
| Registry ID | NCT04374305 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:40:56.982Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04374305
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.